NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

UCB, Inc. 

1950 Lake Park Drive

Smyrna  Georgia  30080  U.S.A.
Phone: 770-437-5705 Fax: 770-437-5640


SEARCH JOBS






Collaborations

The Medicines Company  Contract manufacturing of Bivalirudin peptide active ingredient

Praecis Pharmaceuticals Incorporated  Contract manufacturing of Abarelix peptide active ingredient

Amgen  Contract manufacturing of Abarelix peptide active ingredient

Bausch & Lomb  Contract manufacturing of active pharmaceutical ingredient





 Company News
Ismail Kola joins UCB, Inc. (UCBJF.PK) as Executive Vice President, UCB & President of UCB New Medicines(TM) 11/10/2009 11:17:38 AM    More...
UCB, Inc. (UCBJF.PK): New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure 10/26/2009 9:38:16 AM    More...
UCB, Inc. (UCBJF.PK): New Data Show CIMZIA(R) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohn's Patients 10/26/2009 9:07:33 AM    More...
UCB, Inc. (UCBJF.PK)'s Cimzia(R), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10/19/2009 9:12:11 AM    More...
UCB, Inc. (UCBJF.PK)'s Cimzia(R), The Only Pegylated Anti-TNF, Approved In Europe And Available In A Syringe Designed In Partnership With OXO Good Grips(R) 10/5/2009 10:34:32 AM    More...
UCB, Inc. (UCBJF.PK) And AstraZeneca AB Form Alliance For The Commercialization Of Cimzia(R) In Brazil 9/28/2009 10:56:42 AM    More...
UCB, Inc. (UCBJF.PK) Selects Cambridge Semantics for Enterprise-Wide Semantic Technology Solution 9/8/2009 8:52:22 AM    More...
UCB, Inc. (UCBJF.PK), Immunomedics, Inc. (IMMU) Lupus Treatment Shows Success; IMMU Shares Soar 8/27/2009 6:47:04 AM    More...
FDA Approves UCB, Inc. (UCBJF.PK), Sanofi-Aventis (France) (SASY.PA)'s XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 8/24/2009 12:11:31 PM    More...
UCB, Inc. (UCBJF.PK) and Novartis Corporation (NVS) (JOBS) to Expand Cooperation in Germany 8/24/2009 6:37:39 AM    More...
1234567